SEC Form 4 · accession 0001104659-17-021402
SUPERNUS PHARMACEUTICALS, INC. · SUPN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jack A. Khattar
Officer — President, CEO · Director
Period of report
Apr 3, 2017
Accepted (ET)
Apr 4, 2017 · 4:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001356576
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 3, 2017 | J | 4,250 | — | A | 449,909 | D | |
| Common StockF1 | Apr 3, 2017 | J | 4,250 | — | D | 1,089,750 | I | By the KBT Trust |
| Common StockF2 | holding | — | — | — | 2,250 | I | By son |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The Reporting Person is filing this Form 4 to reflect the fact that 4,250 shares were transferred from the KBT Trust to the Reporting Person on April 3, 2017 without consideration and are now owned directly.
- F2The Reporting Person disclaims beneficial ownership of the shares held by his son, who shares the Reporting Person's household, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose.